Gastrointestinal Cancers (Issue 1) | Special Reports

<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data

February 25, 2014

Clinical Articles

RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for panitumumab in mCRC, according to an analysis of phase III, second-line data, which are consistent with previously reported data in first-line mCRC.

New Standard of Neoadjuvant Care for Rectal Cancer Established

February 24, 2014

Clinical Articles

Findings from the NSABP R-04 trial demonstrated that neoadjuvant capecitabine combined with radiation therapy had outcomes similar to previously established standards of care for stage II or III rectal cancer.

Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer

February 24, 2014

Clinical Articles

Add-on treatment with the hedgehog pathway inhibitor vismodegib demonstrated encouraging activity in patients with untreated metastatic pancreatic ductal adenocarcinoma, according to preliminary data from an ongoing trial.

TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC

February 24, 2014

Clinical Articles

Treatment with an inhibitor of TGF-β led to significant reductions in a prespecified biomarker that correlated with increased TTP and OS in patients with advanced HCC, according to results of a phase II clinical trial.